Preventing Unnecessary Radiotherapy for Patients with Early-Stage Hodgkin’s Lymphoma
By MedImaging International staff writers Posted on 27 Apr 2015 |
Image: PET scan images (Courtesy of King’s College London).
A new study suggested that patients with early-stage (stage 1a or 2a) Hodgkin’s lymphoma disease, who underwent three cycles of chemotherapy with the drugs doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD), and presented negative findings from Positron-Emission Tomography (PET), did not need additional field radiotherapy.
The study data was provided by a UK National Cancer Research Institute trial led by the University of Manchester (Manchester, UK) and the Christie NHS Foundation Trust, and published in the April 23, 2015, edition of the New England Journal of Medicine (NEJM).
The study included a total of 602 patients. PET scanning revealed that the findings were negative in 426 patients. 209 of these patients received radiotherapy, and 211 patients received no further treatment. Patients in both groups were monitored for a period of 5 years.
The results of the study showed that patients with early-stage Hodgkin’s lymphoma who presented with negative PET findings, and had completed three cycles of chemotherapy had a very good prognosis either with or without consolidation radiotherapy. The survival rate of the group of 211 patients that received no further treatment was 90.8%.
Leader researcher of the study, Prof. John Radford, based at the University of Manchester, said, “This research is an important step forward. The results of RAPID show that in early stage Hodgkin lymphoma radiotherapy after initial chemotherapy marginally reduces the recurrence rate, but this is bought at the expense of exposing to radiation all patients with negative PET findings, most of whom are already cured.”
Related Links:
University of Manchester
The study data was provided by a UK National Cancer Research Institute trial led by the University of Manchester (Manchester, UK) and the Christie NHS Foundation Trust, and published in the April 23, 2015, edition of the New England Journal of Medicine (NEJM).
The study included a total of 602 patients. PET scanning revealed that the findings were negative in 426 patients. 209 of these patients received radiotherapy, and 211 patients received no further treatment. Patients in both groups were monitored for a period of 5 years.
The results of the study showed that patients with early-stage Hodgkin’s lymphoma who presented with negative PET findings, and had completed three cycles of chemotherapy had a very good prognosis either with or without consolidation radiotherapy. The survival rate of the group of 211 patients that received no further treatment was 90.8%.
Leader researcher of the study, Prof. John Radford, based at the University of Manchester, said, “This research is an important step forward. The results of RAPID show that in early stage Hodgkin lymphoma radiotherapy after initial chemotherapy marginally reduces the recurrence rate, but this is bought at the expense of exposing to radiation all patients with negative PET findings, most of whom are already cured.”
Related Links:
University of Manchester
Latest Nuclear Medicine News
- New PET Agent Rapidly and Accurately Visualizes Lesions in Clear Cell Renal Cell Carcinoma Patients
- New Imaging Technique Monitors Inflammation Disorders without Radiation Exposure
- New SPECT/CT Technique Could Change Imaging Practices and Increase Patient Access
- New Radiotheranostic System Detects and Treats Ovarian Cancer Noninvasively
- AI System Automatically and Reliably Detects Cardiac Amyloidosis Using Scintigraphy Imaging
- Early 30-Minute Dynamic FDG-PET Acquisition Could Halve Lung Scan Times
- New Method for Triggering and Imaging Seizures to Help Guide Epilepsy Surgery
- Radioguided Surgery Accurately Detects and Removes Metastatic Lymph Nodes in Prostate Cancer Patients
- New PET Tracer Detects Inflammatory Arthritis Before Symptoms Appear
- Novel PET Tracer Enhances Lesion Detection in Medullary Thyroid Cancer
- Targeted Therapy Delivers Radiation Directly To Cells in Hard-To-Treat Cancers
- New PET Tracer Noninvasively Identifies Cancer Gene Mutation for More Precise Diagnosis
- Algorithm Predicts Prostate Cancer Recurrence in Patients Treated by Radiation Therapy
- Novel PET Imaging Tracer Noninvasively Identifies Cancer Gene Mutation for More Precise Diagnosis
- Ultrafast Laser Technology to Improve Cancer Treatment
- Low-Dose Radiation Therapy Demonstrates Potential for Treatment of Heart Failure